Redeye leaves its comments on Idogen following its Q4 report. The company has paused its ongoing phase l/lla-trial and the financial position is stressed. We lower our fair value range accordingly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Idogen Q4 2022 - The future is contingent on funding

© Modular Finance, source Nordic Press Releases